Home Cart Sign in  
Chemical Structure| 1421-65-4 Chemical Structure| 1421-65-4
Chemical Structure| 1421-65-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Synonyms: L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride; Melevodopa hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Methyl L-DOPA HCl

CAS No. :1421-65-4
Formula : C10H14ClNO4
M.W : 247.68
SMILES Code : O=C(OC)[C@@H](N)CC1=CC=C(O)C(O)=C1.[H]Cl
Synonyms :
L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride; Melevodopa hydrochloride
MDL No. :MFCD00038958
InChI Key :WFGNJLMSYIJWII-FJXQXJEOSA-N
Pubchem ID :10131132

Safety of Methyl L-DOPA HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of Methyl L-DOPA HCl

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1421-65-4 ]

[ 1421-65-4 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 67561-03-9 ]
  • [ 1421-65-4 ]
  • [ 880262-98-6 ]
  • 2
  • [ 60656-87-3 ]
  • [ 1421-65-4 ]
  • [ 880262-24-8 ]
  • 3
  • [ 1421-65-4 ]
  • [ 145525-27-5 ]
  • 7,8-dihydroxy-1,2,3,4,3',4'-hexahydro-1'<i>H</i>-[1,3']biisoquinolinyl-3,2'-dicarboxylic acid 2'-<i>tert</i>-butyl ester 3-methyl ester [ No CAS ]
  • 6,7-dihydroxy-1,2,3,4,3',4'-hexahydro-1'<i>H</i>-[1,3']biisoquinolinyl-3,2'-dicarboxylic acid 2'-<i>tert</i>-butyl ester 3-methyl ester [ No CAS ]
  • [ 879287-96-4 ]
  • 4
  • [ 1421-65-4 ]
  • [ 77-78-1 ]
  • [ 145525-27-5 ]
  • [ 879288-01-4 ]
  • [ 879288-00-3 ]
  • 5
  • [ 1421-65-4 ]
  • [ 1200-22-2 ]
  • (S)-3-(3,4-Dihydroxy-phenyl)-2-((R)-5-[1,2]dithiolan-3-yl-pentanoylamino)-propionic acid methyl ester [ No CAS ]
  • 6
  • [ 1421-65-4 ]
  • [ 100-52-7 ]
  • C17H17NO4 [ No CAS ]
  • 7
  • [ 1421-65-4 ]
  • [ 100-52-7 ]
  • C17H17NO4 [ No CAS ]
  • C15H13NO2 [ No CAS ]
  • 8
  • [ 331-39-5 ]
  • [ 1421-65-4 ]
  • [ 120094-83-9 ]
YieldReaction ConditionsOperation in experiment
40% Caffeic acid (140.7 mg, 0.78 mmol) was dissolved in CH2Cl2/DMF (1:3, 3.0 mL), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide(EDC) (247 mL, 147 mmol) and 1-hydroxy-benzotriazole(HOBt) (75.4 mg, 0.56 mmol) were added to the solution. After themixture was cooled in an ice-water bath for 15 min, Et3N (156 mL,1.12 mmol) and compound a (138.3 mg, 0.56 mmol) were added tothe mixture. After stirring at room temperature for 19 h, the mixturewas poured into H2O (50 mL), extracted with EtOAc (50 mL 3), washed with 5% NaHCO3 (150 mL) and brine (150 mL), driedover MgSO4, filtered, and the solvent removed in vacuo. The residue was purified by silica gel column chromatography (CHCl3:MeOH =9:1) to afford clovamide methyl ester (clovamide-Me, 10, 84.7 mg,40%) as a yellow powder: 1H NMR (CD3OD) d 7.36 (1H, d, J = 15.7Hz, H-70), 6.99 (1H, d, J = 1.9 Hz, H-2), 6.89 (1H, dd, J = 8.2, 1.9 Hz,H-6), 6.75 (1H, d, J = 8.2 Hz, H-5), 6.64 (1H, d, J = 1.9 Hz, H-20),6.67 (1H, d, J = 8.1 Hz, H-50), 6.53 (1H, dd, J = 8.1, 1.9 Hz, H-60),6.41 (1H, d, J = 15.7 Hz, H-80), 4.69 (1H, m, H-8), 3.68 (3H, s,MeO-90), 3.02 (1H, dd, J = 13.9, 5.9 Hz, H-7a), 2.93 (1H, dd, J =13.9, 6.6 Hz, H-7b); 13C NMR (CD3OD) d 174.6 (C, C-9), 169.8(C, C-90), 149.5 (C, C-40), 147.3 (C, C-30), 146.8 (C, C-3), 145.9(C, C-4), 143.8 (CH, C-70), 130.2 (C, C-1), 128.9 (C, C-10), 123.1(CH, C-60), 122.4 (CH, C-6), 118.4 (CH, C-80), 118.0 (CH, C-2),117.2 (CH, C-5), 117.1 (CH, C-50), 115.9 (CH, C-20), 56.5 (CH, C-8),53.4 (CH3, CO-9) 39.1 (C, C-7); UV kmax (MeOH) nm (e): 208(12400), 220 (12100), 291 (9700), 324 (10700); HR-ESI-MS (negativeion) m/z: 372.1100 [MH] (calcd for C19H18NO7, 372.1083);[a]D20 +20 (c = 1.0, MeOH).
33.2% General procedure: To a solution of the corresponding substitutedacid (1 eq, 2.02 mmol) in dichloromethane-N,N-dimethylformamide(DMF) (3 : 1, 20 mL) was added 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (1 eq, 2.02 mmol),N,N-diisopropylethylamine (DIEA) (1 eq, 2.02 mmol) andN-hydroxybenzotriazole (HOBt) (1 eq, 2.02 mmol). After themixture was stirred at room temperature for 30 min, correspondingamine (1 eq, 2.02 mmol) and triethylammoniumacetate (TEA) (3 eq, 6.06 mmol) was added. The solution wasstirred at room temperature for 4 h and then extracted withdichloromethane. The organic layer was washed with 1 N HClsolution, saturated NaHCO3 solution, water and brine, driedover Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography (ethylacetate-hexane, 1 : 2) to obtain the title compound.
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In acetonitrile; at 20℃; General procedure: As shown in Scheme 1, the synthetic route of the analogues (1-7) involved a two-step sequence viamethyl esterification of L-amino acidand amide condensation. 100 muL SOCl2was added in portions to 4 mL methanol at -10 C,then 1 mmol L-amino acid was addedand the mixture was warmed to room temperature and stirred overnight. After thesolvent was removed, 5 mL CH3CN, 500 muL DIPEA (N,N-Diisopropyl ethylamine), 1.1 mmolcorresponding substituted acid and 1.1 mmol HBTU (O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluorophosphate)was added into the residue. The mixture was stirred for 1 h at room temperatureto finish condensation. The reaction solution was added 20 mL 1 M HCl, andextracted with ethyl acetate (4 × 20 mL). The combined organic phasewas dried over anhydrous Na2SO4 and finally evaporated invacuum. The residue was purified by silica-gel chromatography using mixtures ofPE/EtOAcas eluent to afford compounds 1-7.At this stage, all compounds were fully analyzed and characterized by nuclearmagnetic resonance (NMR), high resolution massspectrum (HRMS).
  • 10
  • [ 1421-65-4 ]
  • C22H26N2O3 [ No CAS ]
  • 15
  • [ 1421-65-4 ]
  • C22H26N2O2 [ No CAS ]
  • 16
  • [ 1421-65-4 ]
  • C23H29N3O2 [ No CAS ]
  • 17
  • [ 1421-65-4 ]
  • C31H31N3O4 [ No CAS ]
  • 18
  • [ 1421-65-4 ]
  • C33H33F5N2O6 [ No CAS ]
  • 25
  • [ 1421-65-4 ]
  • C25H32N2O6 [ No CAS ]
  • 29
  • [ 1421-65-4 ]
  • C28H33N3O6 [ No CAS ]
  • 31
  • [ 1421-65-4 ]
  • (1R,3S)-1-Benzyloxymethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester; hydrochloride [ No CAS ]
  • 32
  • [ 1421-65-4 ]
  • C28H35N3O6 [ No CAS ]
  • 35
  • [ 1421-65-4 ]
  • C29H33N3O6 [ No CAS ]
 

Historical Records

Technical Information

Categories